United Kingdom (UK)
Recombinant monoclonal antibody to Ebola Nucleoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody KZ51.
Alternative Name(s) of Target: NP; Ebola NP; EBOV NP
Immunogen: This antibody was derived from a human survivor of the 1995 Kikwit outbreak of Ebola.
Specificity: This antibody binds to the nucleoprotein of four Ebola virus strains and has a specificity found in convalescent patients. No cross-reactivity with other proteins (e.g. GP) was detected by radioimmunoprecipitation.
Application Notes: This antibody is broadly cross-reacting between different Ebola strains and competes with antibodies naturally occuring in covalescent patients. By IF, this antibody has higher reactivity towards fixed virus than to live virus - though both may be detected. It has also been used as a positive control in the development of anti-Ebola polyclonal goat antibodies (Boisen et al. 2015).
Antibody first published in:
Maruyama et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999 Jul; 73(7): 6024–6030. PMID:10364354
Note on publication:
Describes the generation and functional characterization of this antibody.